Clinical trial
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer…
NCT00122681 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00122681 |
|---|---|
| Title | Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 |
| Official title | A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Cervarix™, Havrix™-based investigational formulation |
| Enrollment | 18,729 |
| Start date | May 6, 2004 |
| Primary completion | Nov 3, 2006 |
| Completion | Nov 26, 2009 |
| First posted | Jul 22, 2005 |
| Last update posted | Aug 20, 2018 |
| Countries | Australia, Belgium, Brazil, Canada, Finland, Germany, Italy, Mexico, Philippines, Spain, Taiwan, Thailand and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: